CenterBook Partners LP Purchases New Stake in Neuronetics, Inc. (NASDAQ:STIM)

CenterBook Partners LP purchased a new position in Neuronetics, Inc. (NASDAQ:STIM - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 326,126 shares of the company's stock, valued at approximately $1,200,000. CenterBook Partners LP owned approximately 0.50% of Neuronetics at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Larson Financial Group LLC bought a new position in Neuronetics during the first quarter valued at approximately $25,000. Geode Capital Management LLC grew its holdings in Neuronetics by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 314,076 shares of the company's stock valued at $506,000 after purchasing an additional 8,466 shares during the last quarter. KPP Advisory Services LLC acquired a new position in Neuronetics during the first quarter valued at approximately $37,000. Presidio Capital Management LLC acquired a new position in Neuronetics during the first quarter valued at approximately $44,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Neuronetics during the first quarter valued at approximately $55,000. 53.59% of the stock is owned by hedge funds and other institutional investors.

Neuronetics Stock Performance

Shares of Neuronetics stock traded down $0.17 during midday trading on Friday, hitting $3.66. The company had a trading volume of 516,954 shares, compared to its average volume of 853,224. The business's 50 day simple moving average is $3.75 and its two-hundred day simple moving average is $3.77. The stock has a market cap of $241.96 million, a PE ratio of -2.79 and a beta of 1.85. The company has a debt-to-equity ratio of 1.40, a current ratio of 2.44 and a quick ratio of 2.28. Neuronetics, Inc. has a 1-year low of $0.52 and a 1-year high of $5.92.

Neuronetics (NASDAQ:STIM - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Neuronetics had a negative return on equity of 174.15% and a negative net margin of 53.67%. The company had revenue of $31.98 million during the quarter, compared to analyst estimates of $29.07 million. As a group, equities analysts predict that Neuronetics, Inc. will post -1.13 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Stephen Furlong sold 193,460 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $4.27, for a total transaction of $826,074.20. Following the completion of the sale, the executive vice president directly owned 416,593 shares of the company's stock, valued at approximately $1,778,852.11. This represents a 31.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 9.80% of the company's stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.